肽受体放射性核素治疗十二年随访结果
这项回顾性临床研究纳入44例晚期生长抑素受体高表达肿瘤患者,分析90Y-DOTATOC与177Lu-DOTATATE肽受体放射性核素治疗(PRRT)的长期结局。中位随访80个月,中位总生存79个月;PRRT开始12年后14/44例(32%)仍存活。初始PRRT后疾病进展者预后较差(log rank,P < 0.001),女性及肿瘤部位不超过2个者似乎尤其获益(未达统计学显著)。
要点
- 44例晚期肿瘤患者接受PRRT,中位随访80个月,中位总生存79个月。
- PRRT开始12年后14/44例(32%)仍存活,最短病程8个月、最长155个月。
- 初始PRRT后进展者预后较累积疾病控制者差(log rank,P < 0.001)。
核心结论
- PRRT在长期结局方面令人鼓舞。
- 32%(14/44例)转移性或不可手术疾病患者在放射性核素治疗开始后超过12年仍存活。
- 有利结局的可能预测因素为对PRRT有初始反应、受累部位数量少以及女性。
研究设计与样本
- 回顾性临床研究,纳入44例连续患者(27例男性)的晚期肿瘤且生长抑素受体表达增强。
- 首次诊断时平均年龄60岁(SD,11.3岁;范围,40-84岁),中位随访80个月。
- 177Lu-PRRT平均给药周期数5.3 ± 2.5,每例患者平均活度27.2 ± 14.9 GBq。
- 90Y-PRRT平均给药周期数5.5 ± 2.6,每例患者平均活度14.7 ± 7.3 GBq。
- 共给药378个周期(每例患者平均8.6 ± 3.4个周期),总累积活度1,514.1 GBq。
主要发现
- 中位总生存79个月。
- PRRT开始12年后,27例男性中21例(77.8%)死亡,17例女性中9例(52.9%)死亡。
- 最短病程8个月,最长155个月。
- 14例仍存活患者中9例出现严重副作用(世界卫生组织III级和IV级),慢性肾脏病合并贫血是这9例严重副作用患者中最常见的表现。
- 初始PRRT后疾病进展者预后较累积疾病控制者差(log rank,P < 0.001)。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Peptide receptor radionuclide therapy (PRRT) has been used for more than 20 y as a systemic treatment approach in inoperable or metastatic somatostatin receptor-positive tumors. The purpose of this study was to analyze the long-term outcome of PRRT with regard to the most commonly used radiopharmaceuticals, 90Y-DOTATOC and 177Lu-DOTATATE. Methods: This retrospective clinical study included a total of 44 consecutive patients (27 men) with advanced tumors and enhanced somatostatin receptor expression. Mean age at initial diagnosis was 60 y (SD, 11.3 y; range, 40-84 y). Median follow-up was 80 mo. For 177Lu-PRRT, the mean number of cycles administered was 5.3 ± 2.5 and the mean activity was 27.2 ± 14.9 GBq per patient. For 90Y-PRRT, the mean number of cycles administered was 5.5 ± 2.6 and the mean activity was 14.7 ± 7.3 GBq per patient. Overall, 378 cycles were administered (mean, 8.6 ± 3.4 cycles per patient), with an overall cumulative activity of 1,514.1 GBq. Results: Median overall survival was 79 mo. Twenty-one (77.8%) of the 27 men and 9 (52.9%) of the 17 women had died 12 y after commencement of PRRT. The shortest duration of illness was 8 mo and the longest 155 mo. Severe side effects (World Health Organization grades III and IV) were seen in 9 of the 14 patients still alive. Chronic kidney disease in combination with anemia was the most common finding in the 9 patients with severe side effects. A poor prognosis was found for those patients who showed progressive disease, in comparison with patients with cumulative disease control after initial PRRT (log rank, P < 0.001), whereas women and patients with no more than 2 tumor sites seemed to especially benefit from PRRT (not reaching significance levels). Conclusion: PRRT is encouraging in terms of long-term outcome. Thirty-two percent (14/44 patients) of the patients with metastatic or inoperable disease were still alive more than 12 y after the beginning of radionuclide therapy. Possible predictors for favorable outcome are having an initial response to PRRT, having a low number of affected sites, and being female.
引用
- Gabriel M, Nilica B, Kaiser B, et al. Twelve-Year Follow-up After Peptide Receptor Radionuclide Therapy. J Nucl Med. 2018. PMID: 30115690. doi:10.2967/jnumed.118.215376
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。